6493-05-6 Usage
Chemical Properties
White to Off-White Solid
Originator
Trental,Albert Roussel ,W. Germany ,1972
Uses
Different sources of media describe the Uses of 6493-05-6 differently. You can refer to the following data:
1. Pentoxifylline is a methylxanthine phospho-diesterase inhibitor with favorable antiinflammatory effects and immunoregulatory properties.A metabolite of Pentifylline. Methylxanthine derivative that improves blood flow by decreasing blood viscosity. Phosphodiesterase inhibitor. Inhibits the synthesis of tumor necrosis factor a (TNF-a).
2. Pentoxifylline can increase red blood cell deformability, reduce blood viscosity, and decrease platelet aggregation and thrombus formation. Pentoxifylline is an oral agent that improves perfusion of occluded vessels and is used to treat systemic vascular diseases. The retinal flow velocity in patients with RVO treated with pentoxifylline improved compared with placebo, but the study had a small number of patients (n = 8) and short follow-up (4 weeks), and no visual outcome data were reported.
3. Pentoxifylline has been used:used in the combinatorial treatment with itraconazole for paracoccidioidomycosis (PCM)to treat harvested sperms to check the effect of ′pentoxifylline exposed sperms′ in the contribution of embryonic growthto intrathecally inject female and male mice to investigate whether astrocytes and microglia could be causally involved in the maintenance of pain-like behaviour
Indications
Pentoxifylline at a dose of 400 mg three times a day after meals was reported
to alleviate the symptoms in a small open trial.
Manufacturing Process
A solution of 35.4 g of 1-bromohexanone-5 in 200 ml of ethanol was gradually mixed at the reflux temperature with vigorous stirring with 39.7 g of theobromine-sodium in 100 ml of water. After 3 hours reflux the unreacted theobromine was filtered off with suction, the filtrate was evaporated to dryness, the residue was dissolved in water and the solution was extracted with chloroform. The chloroform was distilled off and 1-(5'-oxohexyl)-3,7
Pentoxifylline dimethylxanthine was obtained as residue; after recrystallization from isopropanol, it melted at 102°C to 103°C (about 25% yield, calculated on the reacted theobromine).
Brand name
Pentoxil (Upsher Smith); Trental (Sanofi
Aventis).
Therapeutic Function
Vasodilator
Biological Activity
Phosphodiesterase inhibitor that blocks production of TNF- α and other cytokines. Displays antinociceptive activity.
Biochem/physiol Actions
Pentoxifylline?(PTX) is considered as a nonspecific phosphodiesterase inhibitor. It possesses rheologic properties. Pentoxifylline?is used to treat peripheral vascular disease. It has the ability to block the phosphorylation of I kappa B-alpha (I?Bα) in serines 32 and 36.
Veterinary Drugs and Treatments
In horses, pentoxifylline has been used as adjunctive therapy for cutaneous,
vasculitis, endotoxemia and for the treatment of navicular
disease.
Pentoxifylline has been used in dogs to treat immune-mediated
dermatologic conditions, enhance healing, and reduce inflammation
caused by ulcerative dermatosis in Shelties and Collies and
for other conditions where improved microcirculation may be of
benefit. It is being investigated for adjunctive therapy for dilated
cardiomyopathy in Doberman pinschers.
Pentoxifylline has been tried in conjunction with prednisolone
to decrease vasculitis associated with FIP in cats.
Pentoxifylline’s major indications for humans include symptomatic
treatment of peripheral vascular disease (e.g., intermittent claudication,
sickle cell disease, Raynaud’s, etc.) and cerebrovascular diseases
where blood flow may be impaired in the microvasculature.
Check Digit Verification of cas no
The CAS Registry Mumber 6493-05-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,4,9 and 3 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 6493-05:
(6*6)+(5*4)+(4*9)+(3*3)+(2*0)+(1*5)=106
106 % 10 = 6
So 6493-05-6 is a valid CAS Registry Number.
InChI:InChI=1/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
6493-05-6Relevant articles and documents
Synthesis method of pentoxifylline
-
Paragraph 0026-0030; 0031-0035; 0040-0042, (2021/08/07)
The invention belongs to the field of medicine synthesis, and discloses a synthesis method of pentoxifylline, which is characterized in that 4-(nitrogen methyl acyl chloride)-1-methylimidazole-5-acyl chloride and amino-5-hexanone are subjected to condensation ring closing, and the target product pentoxifylline is synthesized by only one-step reaction. The pentoxifylline synthesis method provided by the invention is simple in synthesis process, and byproducts obtained in the reaction process can be recycled to synthesize pentoxifylline again. The method is suitable for synthesizing pentoxifylline, and the synthesized pentoxifylline is used for preparing pentoxifylline for injection.
Pentoxifylline compound
-
Paragraph 0039; 0042-0046; 0049-0052, (2020/01/12)
The invention discloses a pentoxifylline compound. The compound is measured by using powder X-ray diffractometry and characteristic diffraction peaks are displayed by representing the 2 theta+/- 0.2 degrees at the places of 7.6 degrees, 7.8 degrees, 12.7 degrees, 13.6 degrees and 15.2 degrees. The pentoxifylline compound prepared by the method has the advantages of good stability, high purity andless impurities, and is simple in process, high in yield, strong in repeatability, high in medication safety and effectiveness, the incidence rate of the adverse reactions is greatly reduced, and thepentoxifylline compound is suitable for industrial production.
Glycation Cross-link Breakers to Increase Resistance to Enzymatic Degradation
-
, (2013/12/03)
The present invention relates to a method to treat a grafts, implant, scaffold, and constructs, including allografts, xenografts, autografts, and prosthetics comprising collagen, with an inhibitor of collagen cross-links and/or advanced glycation endproducts (AGE), in order to alleviate the mechanical weakness induced by the cross-links The invention also provides for kits for use in the operating theater during autograft, allograft or xenograft procedures, or for preparing allograft, xenografts or prosthetics that have not been already treated prior to packaging. The kit comprises a first agent or agents that inhibit collagen cross-links and/or advanced glycation endproducts, instructions for use, optionally a wash or rinse agent, and a device for containing the graft and first agent.